DENVER, Colo. (247marketnews.com) -- CorMedix Therapeutics (NASDAQ:CRMD) just delivered another powerful quarter, pairing $101.9 million in Q2 revenue with $58.7 million in adjusted EBITDA while expanding DefenCath’s commercial reach and preparing for a potentially major REZZAYO label expansion.
The numbers tell a striking story. CorMedix reported $101.9 million of consolidated revenue for the second quarter, including $66.1 million from DefenCath and $35.8 million from the Melinta portfolio. Net income reached $26.0 million, while adjusted EBITDA surged to $58.7 million. The company also finished June with $256.7 million in cash and short-term investments, giving management substantial financial flexibility.
The bigger development may be what is happening underneath those financial results. CorMedix has signed a new multi-year DefenCath supply agreement with a large dialysis operator, bringing its commercial contract footprint to all five of the largest U.S. dialysis providers. The new customer has already begun ordering DefenCath and plans to start a pilot in the third quarter. That matters because the U.S. dialysis market is highly concentrated, with the largest providers representing a substantial share of patients and facilities.
There is also a compelling clinical-commercial angle. CorMedix previously reported interim real-world evidence in which DefenCath was associated with a 72% reduction in catheter-related bloodstream infections and a 70% reduction in related hospitalizations versus historical controls. The study involved more than 7,000 patients receiving at least one dose of DefenCath. While those are company-reported observational data and not randomized-trial results, they offer an important piece of evidence for a product designed to prevent serious infections in vulnerable dialysis patients.
Now the company is raising the stakes. CorMedix maintained its 2026 revenue guidance of $325 million to $345 million while increasing adjusted EBITDA guidance to $125 million to $140 million. It also expects to submit an sNDA for an expanded REZZAYO indication covering prophylaxis against invasive fungal disease in the third quarter. If accepted, the company anticipates an FDA decision in the first half of 2027. The potential label expansion could significantly broaden the commercial opportunity for REZZAYO; CorMedix has previously described prophylaxis as a major potential growth driver.
The key wrinkle is reimbursement. CorMedix has warned that the transition from TDAPA reimbursement for DefenCath creates pricing pressure during the second half of 2026. Management has nevertheless maintained its revenue outlook while raising profitability expectations, suggesting that utilization, commercial expansion and the Melinta portfolio are helping offset that pressure. The company is effectively attempting to prove that DefenCath can become a durable commercial franchise even as its reimbursement environment evolves.
For investors, the emerging CRMD story is increasingly less about whether CorMedix can commercialize a single product and more about how large a profitable specialty-pharma platform it can build around DefenCath, REZZAYO and the acquired Melinta portfolio. With a substantial cash position, expanding dialysis contracts, positive real-world evidence and a potentially valuable regulatory catalyst ahead, CorMedix has multiple avenues for growth. The next question is whether continued execution can turn that increasingly diversified opportunity into sustained earnings and cash flow.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.